schliessen

Filtern

 

Bibliotheken

Suppression of ovarian cancer growth via systemic administration with liposome-encapsulated adenovirus-encoding endostatin

Gene therapy using adenoviral vector containing the endostatin gene is a promising strategy for advanced cancers. However, host immune response to adenovirus and the lack of the requisite coxsackie-adenovirus receptor (CAR) in many primary cells limit the in vivo application. Liposome-complexed aden... Full description

Journal Title: Cancer Gene Therapy 2009, Vol.17(1), p.49
Main Author: L Yang
Other Authors: L Wang , X-Q Su , L Wang , X-C Chen , D Li , S-T Luo , H-S Shi , L-J Chen , Y-S Wang
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 0929-1903 ; E-ISSN: 1476-5500 ; DOI: 10.1038/cgt.2009.47
Link: http://dx.doi.org/10.1038/cgt.2009.47
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: nature_a10.1038/cgt.2009.47
title: Suppression of ovarian cancer growth via systemic administration with liposome-encapsulated adenovirus-encoding endostatin
format: Article
creator:
  • L Yang
  • L Wang
  • X-Q Su
  • L Wang
  • X-C Chen
  • D Li
  • S-T Luo
  • H-S Shi
  • L-J Chen
  • Y-S Wang
subjects:
  • Immune Response -- Growth
  • Immune Response -- Health Aspects
  • Ovarian Cancer -- Prognosis
  • Ovarian Cancer -- Drug Therapy
  • Ovarian Cancer -- Research
  • Ovarian Cancer -- Growth
  • Ovarian Cancer -- Risk Factors
  • Ovarian Cancer -- Genetic Aspects
  • Gene Therapy -- Health Aspects
  • Endostatin -- Health Aspects
ispartof: Cancer Gene Therapy, 2009, Vol.17(1), p.49
description: Gene therapy using adenoviral vector containing the endostatin gene is a promising strategy for advanced cancers. However, host immune response to adenovirus and the lack of the requisite coxsackie-adenovirus receptor (CAR) in many primary cells limit the in vivo application. Liposome-complexed adenoviral vectors have proven to be useful for enhancing gene delivery in target cells that lack adenoviral receptors and avoiding a neutralizing antibody response. Here, we investigated antitumor effects of intravenous administration with PEG-PE cationic liposome-encapsulated recombinant human endostatin adenovirus (Ad-hEndo) on CAR-negative ovarian cancer. Electron micrography (EM) showed that these liposomes efficiently encapsulated the vectors, allowing CAR-independent adenovector transduction. The results showed that the complex enhanced transfection efficiency of recombinant adenovirus. Prolonged systemic administration was performed in immunocompetent mice and did not induce significant antibody response. The antitumor effect with PEG-PE cationic liposome encapsulated with Ad-hE (Ad-hE/lipo) was evaluated in the human ovarian cancer model. Systemic administration was well tolerated and resulted in marked suppression of tumor growth in an established ovarian cancer model, which was associated with a decreased number of micro-vessels and increased apoptosis of tumor cells. Our study shows that PEG-PE cationic liposome-encapsulated Ad-hE (Ad-hE/Lipo) can be administrated intravenously and lastingly to inhibit angiogenesis, thus showing promising clinical application. Cancer Gene Therapy (2010) 17, 49-57; doi: 10.1038/cgt.2009.47; published online 17 July 2009 Keywords: PEG-PE liposome; endostatin; adenovirus; gene therapy; ovarian cancer
language:
source:
identifier: ISSN: 0929-1903 ; E-ISSN: 1476-5500 ; DOI: 10.1038/cgt.2009.47
fulltext: fulltext
issn:
  • 0929-1903
  • 09291903
  • 1476-5500
  • 14765500
url: Link


@attributes
ID327515641
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1038/cgt.2009.47
sourceidnature_a
recordidTN_nature_a10.1038/cgt.2009.47
sourcesystemPC
pqid21316536
galeid215304817
display
typearticle
titleSuppression of ovarian cancer growth via systemic administration with liposome-encapsulated adenovirus-encoding endostatin
creatorL Yang ; L Wang ; X-Q Su ; L Wang ; X-C Chen ; D Li ; S-T Luo ; H-S Shi ; L-J Chen ; Y-S Wang
ispartofCancer Gene Therapy, 2009, Vol.17(1), p.49
identifier
source
descriptionGene therapy using adenoviral vector containing the endostatin gene is a promising strategy for advanced cancers. However, host immune response to adenovirus and the lack of the requisite coxsackie-adenovirus receptor (CAR) in many primary cells limit the in vivo application. Liposome-complexed adenoviral vectors have proven to be useful for enhancing gene delivery in target cells that lack adenoviral receptors and avoiding a neutralizing antibody response. Here, we investigated antitumor effects of intravenous administration with PEG-PE cationic liposome-encapsulated recombinant human endostatin adenovirus (Ad-hEndo) on CAR-negative ovarian cancer. Electron micrography (EM) showed that these liposomes efficiently encapsulated the vectors, allowing CAR-independent adenovector transduction. The results showed that the complex enhanced transfection efficiency of recombinant adenovirus. Prolonged systemic administration was performed in immunocompetent mice and did not induce significant antibody response. The antitumor effect with PEG-PE cationic liposome encapsulated with Ad-hE (Ad-hE/lipo) was evaluated in the human ovarian cancer model. Systemic administration was well tolerated and resulted in marked suppression of tumor growth in an established ovarian cancer model, which was associated with a decreased number of micro-vessels and increased apoptosis of tumor cells. Our study shows that PEG-PE cationic liposome-encapsulated Ad-hE (Ad-hE/Lipo) can be administrated intravenously and lastingly to inhibit angiogenesis, thus showing promising clinical application. Cancer Gene Therapy (2010) 17, 49-57; doi: 10.1038/cgt.2009.47; published online 17 July 2009 Keywords: PEG-PE liposome; endostatin; adenovirus; gene therapy; ovarian cancer
subjectImmune Response -- Growth ; Immune Response -- Health Aspects ; Ovarian Cancer -- Prognosis ; Ovarian Cancer -- Drug Therapy ; Ovarian Cancer -- Research ; Ovarian Cancer -- Growth ; Ovarian Cancer -- Risk Factors ; Ovarian Cancer -- Genetic Aspects ; Gene Therapy -- Health Aspects ; Endostatin -- Health Aspects;
version8
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://dx.doi.org/10.1038/cgt.2009.47$$EView_this_record_in_Nature
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0L Yang
1L Wang
2X-Q Su
3X-C Chen
4D Li
5S-T Luo
6H-S Shi
7L-J Chen
8Y-S Wang
titleSuppression of ovarian cancer growth via systemic administration with liposome-encapsulated adenovirus-encoding endostatin
general
0Nature Publishing Group
110.1038/cgt.2009.47
2nature.com (Nature Publishing Group)
sourceidnature_a
recordidnature_a10.1038/cgt.2009.47
issn
00929-1903
109291903
21476-5500
314765500
rsrctypearticle
creationdate2009
searchscopenature_a
scopenature_a
lsr30VSR-Enriched:[galeid, pages, description, subject, eissn, pqid]
sort
titleSuppression of ovarian cancer growth via systemic administration with liposome-encapsulated adenovirus-encoding endostatin
authorL Yang ; L Wang ; X-Q Su ; L Wang ; X-C Chen ; D Li ; S-T Luo ; H-S Shi ; L-J Chen ; Y-S Wang
creationdate20090717
facets
frbrgroupid7743265877850269290
frbrtype5
creationdate2009
collectionnature.com (Nature Publishing Group)
prefilterarticles
rsrctypearticles
creatorcontrib
0L Yang
1L Wang
2X-Q Su
3X-C Chen
4D Li
5S-T Luo
6H-S Shi
7L-J Chen
8Y-S Wang
jtitleCancer Gene Therapy
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0L Yang
1L Wang
2X-Q Su
3X-C Chen
4D Li
5S-T Luo
6H-S Shi
7L-J Chen
8Y-S Wang
atitleSuppression of ovarian cancer growth via systemic administration with liposome-encapsulated adenovirus-encoding endostatin
jtitleCancer Gene Therapy
risdate20090717
volume17
issue1
spage49
issn0929-1903
genrearticle
ristypeJOUR
pubNature Publishing Group
doi10.1038/cgt.2009.47
pages49-57
eissn14765500
date2009-07-17